Stocksigma LogoStocksigma Logo

Bacil Pharma Reports Q2 FY27 Loss of Rs 7.22 Lakh Amid Operational Inactivity

Bacil Pharma reported nil revenue from operations for Q2 ended 30th Sep'26, relying entirely on other income of Rs 9.18 lakh (up 3.0% QoQ)

Bacil Pharma Reports Q2 FY27 Loss of Rs 7.22 Lakh Amid Operational Inactivity

Bacil Pharma Ltd 路 Financial Result 路 14 Oct 2026, 9:46 pm

Bacil Pharma Reports Q2 FY27 Loss of Rs 7.22 Lakh Amid Operational Inactivity Bacil Pharma reported nil revenue from operations for Q2 ended 30th Sep'26, relying entirely on other income of Rs 9.18 lakh (up 3.0% QoQ). Consolidated net loss widened to Rs 7.22 lakh versus a loss of Rs 1.61 lakh in Q1 ended 30th Jun'26, heavily impacted by deferred tax expenses of Rs 4.23 lakh and finance costs of Rs 6.24 lakh. Basic and diluted EPS stood at Rs 0.06. Total consolidated assets stood at Rs 3,081.30 lakh, supported by current borrowings of Rs 552.24 lakh.

Original exchange filing (PDF)

More announcements from Bacil Pharma Ltd

All Bacil Pharma Ltd announcements